Physician

Matthew Hans Gonzalez, M.D.

According to 2025 Medicare claims, Matthew Gonzalez, M.D. (NPI: 1639445844) practices advanced heart failure and transplant cardiology in the Grand Rapids-Wyoming-Kentwood, MI market, with the plurality of this provider's patient population coming from Kent, MI. This provider's primary affiliated billing organization is SPECTRUM HEALTH PRIMARY CARE PARTNERS (NPI: 1235188673; TIN: 381358164) and primary practice location at 49503-2560. Gonzalez is affiliated with the POM ACO (ACO ID: A1297) and West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Gonzalez's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 269 traditional Medicare patients, billed 617 HCPCS/CPT codes, and received $48,387 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 2,609 prescription claims across 418 beneficiaries totaling $3,365,228 in drug costs, led by Vyndamax (Tafamidis). DME data shows 38 claims. Open Payments data shows 20 records totaling $2,160. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $18,648 and ending at $48,387. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $14,693 to $3,365,228. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	210	428	$18,648
2020	558	1,079	$53,009
2021	552	936	$52,795
2022	402	620	$32,399
2023	414	781	$51,227
2024	269	617	$48,387

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	146	513	$14,693
2016	42	112	$2,663
2017	N/R	16	$1,756
2018	N/R	N/R	N/R
2019	46	96	$9,506
2020	216	1,065	$302,757
2021	314	2,141	$754,091
2022	419	2,952	$1,480,868
2023	422	2,838	$2,658,169
2024	418	2,609	$3,365,228

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	33	$15,431
2021	N/R	N/R	N/R
2022	N/R	11	$769
2023	N/R	88	$9,927
2024	N/R	38	$4,447

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	23	64	$167
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	61	79	$112
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	47	82	$94
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	56	56	$54
G0250	Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent	22	24	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	93	2,790	$2,208,152
Vyndaqel	Tafamidis Meglumine	18	540	$411,365
Entresto	Sacubitril/Valsartan	301	15,620	$328,006
Eliquis	Apixaban	136	7,791	$143,836
Farxiga	Dapagliflozin Propanediol	144	7,350	$130,816

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	13	$2,946
J2260	Injection, milrinone lactate, 5 mg	N	N/R	13	$1,271
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	12	$230

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$1,993	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$166	Abbott Laboratories
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matthew Hans Gonzalez, M.D.?

Tedicare shows public-source Medicare data for Matthew Hans Gonzalez, M.D. (NPI 1639445844), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew Hans Gonzalez, M.D. have ACO affiliation data?

Matthew Hans Gonzalez, M.D. is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297) and West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Matthew Hans Gonzalez, M.D.?

Matthew Hans Gonzalez, M.D. is linked to SPECTRUM HEALTH PRIMARY CARE PARTNERS (billing NPI 1235188673) in the available physician profile data.

Does Matthew Hans Gonzalez, M.D. have Open Payments data?

Matthew Hans Gonzalez, M.D. has 20 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.